M&A In The Pharmaceutical Industry: Balancing Innovation And Regulation
M&A in the pharmaceutical industry is looking at an exceptional surge in activity in 2024 and the upcoming years. Mergers and acquisitions are the most viable strategies for companies to expand their R&D efforts and market presence. Capturing broader geographical markets and customer demographics while economizing on costs are only some of the benefits. Pooling resources, expenses, technical know-how, and talent proves to be beneficial to the participants if they can achieve optimum synergies.
M&A in the pharmaceutical industry is looking at an exceptional surge in activity in 2024 and the upcoming years. Mergers and acquisitions are the most viable strategies for companies to expand their R&D efforts and market presence.
Capturing broader geographical markets and customer demographics while economizing on costs are only some of the benefits. Pooling resources, expenses, technical know-how, and talent proves to be beneficial to the participants if they can achieve optimum synergies.
Although the biopharma and pharmaceutical industries continue to grow exponentially, particular sectors are likely to experience higher growth than others. A study of the vertical’s growth patterns starting from the pandemic reveals that M&A activity and investment have been gaining ground.
*FREE DOWNLOAD*
The Ultimate Guide To Pitch Decks
Let’s Check Out Some Statistics
Mergers and acquisitions increased in volume in 2023 despite the skyrocketing interest rates and federal regulations becoming stricter. Statistics indicate that the growth was more than 30% and surpassed
00B in disclosed value.
Experts also estimate that activity levels will likely grow from
Rare diseases and immunology are two sectors coming up second and third by value of deals. mRNA therapy or treatment options using messenger genes to deliver genetic information to DNA are also gaining traction.
In the last few years, M&A in the pharmaceutical industry has been triggered mainly by mid-sized firms. But, in 2023, most deals were initiated by the big pharma companies looking to grab innovative biotechnology firms.
Since this is a capital-intensive industry, acquiring smaller startups is always preferable to investing in in-house labs. R&A requires significant resources but without any specific timeline for getting results.
Notable examples include Pfizer’s $43B acquisition of Seagen and Bristol Myers Squibb’s
4B M&A deal with Karuna Therapeutics. The
7.8B acquisition of Horizon Therapeutics by Amgen and AbbVie’s 0.1B Immunogen purchase are other deals making waves in the industry.
Specific Sectors Are Experiencing More Activity
Continue reading the full guide
Related guides
Read on Startup Fundraising ·
More articles ·
Browse the Library
